Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981-983.
Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Aucjl). 2016;6:131-144.
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermat. 2018;27:1067-1077.
Borges-Costa J, Silva R, Gonçalves L, et al. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12:271-276.
Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53:676-684.
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235-1270.
Gooderham MJ, Van Voorhees AS, Lebwohl M. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907-919.
Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109-120.
Kharawala S, Golembesky AK, Bohn RL, et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16:239-252.
Ly K, Beck KM, Smith MP, et al. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37-42.
Mirza H, Badri T, Eddie Kwan. Generalized Pustular Psoriasis. In: StatPearls [Internet]. StatPearls Publishing; 2020 January. Updated September 15, 2020. https://www.ncbi.nlm.nih.gov/books/NBK493189/
Nagata M, Kamata M, Fukaya S, et al. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab. J Am Acad Dermatol. 2020;82:758-761.
Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792-1799.
Neurath MF. IL-36 in chronic inflammation and cancer. Cytokine Growth Factor Rev. 2020;55:70-79.
Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529-539.
Takeichi T, Akiyama M. Generalized pustular psoriasis: clinical management and update on autoinflammatory aspects. Am J Clin Dermatol. 2020;21:227-236.
Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021-1026.
Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2020. doi: 10.1038/s41423-020-0519-3. [Epub ahead of print]
Viguier M, Aubin F, Delaporte E, et al; Goupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012;148:1423-1425.
Yamasaki K, Nakagawa H, Kubo Y, et al; Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741-751.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Melinda Gooderham, MD

Assistant Professor
Queens University
Kingston, Ontario, Canada
Probity Medical Research
Waterloo, Ontario, Canada
Medical Director
SKiN Centre for Dermatology
Investigator
Consultant Physician
Peterborough Regional Health Centre
Peterborough, Ontario, Canada

Disclosures

Disclosure: Melinda Gooderham, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Arcutis; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Kyowa Kirin; LEO; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Ltd.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Genzyme Corporation; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB Pharma, Inc.; Valeant Pharmaceuticals International
Received grants for clinical research from: AbbVie Inc.; Akros; Amgen Inc.; Arcutis; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; Eli Lilly and Company; Galderma Laboratories, L.P.; Incyte Corporation; Janssen Pharmaceuticals; Kyowa Kirin; LEO Pharma; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme Corporation; Sun Pharmaceutical Industries, Ltd.; Valeant Pharmaceuticals International

Editors

Briana Betz, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Briana Betz, PhD, has disclosed no relevant financial relationships.

Heather Lewin, MAT

Director, WebMD Global, LLC

Disclosures

Disclosure: Heather Lewin, MAT, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

Challenges and Opportunities in the Management of Generalized Pustular Psoriasis

Authors: Melinda Gooderham, MD
CPD Released: 12/4/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/4/2021

Start Activity

Target Audience and Goal Statement

This activity is intended for an international audience of non-US dermatologists and primary care physicians involved in the management of patients with generalized pustular psoriasis (GPP).

The goal of this activity is to describe clinical presentation of GPP and the impact on patients' lives, and as well as to provide top experts' tips on practical aspects of GPP management to optimize patient outcomes.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Etiopathogenesis of GPP
- Impact of GPP on patients' lives
Have greater confidence related to
- Managing patients with GPP to optimize patient outcomes

Disclosures

Faculty

Melinda Gooderham, MD

Assistant Professor
Queens University
Kingston, Ontario, Canada
Probity Medical Research
Waterloo, Ontario, Canada
Medical Director
SKiN Centre for Dermatology
Investigator
Consultant Physician
Peterborough Regional Health Centre
Peterborough, Ontario, Canada

Disclosures

Disclosure: Melinda Gooderham, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Arcutis; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Kyowa Kirin; LEO; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Ltd.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Galderma Laboratories, L.P.; Genzyme Corporation; Janssen Pharmaceuticals; LEO Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; UCB Pharma, Inc.; Valeant Pharmaceuticals International
Received grants for clinical research from: AbbVie Inc.; Akros; Amgen Inc.; Arcutis; Bristol Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; Eli Lilly and Company; Galderma Laboratories, L.P.; Incyte Corporation; Janssen Pharmaceuticals; Kyowa Kirin; LEO Pharma; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme Corporation; Sun Pharmaceutical Industries, Ltd.; Valeant Pharmaceuticals International

Editors

Briana Betz, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Briana Betz, PhD, has disclosed no relevant financial relationships.

Heather Lewin, MAT

Director, WebMD Global, LLC

Disclosures

Disclosure: Heather Lewin, MAT, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Challenges and Opportunities in the Management of Generalized Pustular Psoriasis

Authors: Melinda Gooderham, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 12/4/2020

Valid for credit through: 12/4/2021

processing....

Full Live Event Video

« Return to: Challenges and Opportunities in the Management of Generalized Pustular Psoriasis

CPD Information Download Slides

Full Live Event Video

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Melinda Gooderham, MD

Editors

Briana Betz, PhD

Heather Lewin, MAT

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

Challenges and Opportunities in the Management of Generalized Pustular Psoriasis

Target Audience and Goal Statement

Disclosures

Faculty

Melinda Gooderham, MD

Editors

Briana Betz, PhD

Heather Lewin, MAT

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Challenges and Opportunities in the Management of Generalized Pustular Psoriasis

Full Live Event Video